Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-in-human studies for ZW209 and ZW1528 anticipated in 2026 Phase 3 HERIZON-GEA-01 top-line results for Ziihera®
01.08.2025
